Appendix F
Guideline Standards: The AGREE Instrument and COGS Checklist

THE APPRAISAL OF GUIDELINES RESEARCH AND EVALUATION (AGREE) INSTRUMENT1

Scope and Purpose

  1. The overall objective(s) of the guideline is (are) specifically described.

  2. The clinical question(s) covered by the guideline is (are) specifically described.

  3. The patients to whom the guideline is meant to apply are specifically described.

Stakeholder Involvement

  1. The guideline development group includes individuals from all the relevant professional groups.

  2. The patients’ views and preferences have been sought.

  3. The target users of the guideline are clearly defined.

  4. The guideline has been piloted among target users.

Rigour of Development

  1. Systematic methods were used to search for evidence.

  2. The criteria for selecting the evidence are clearly described.

  3. The methods used for formulating the recommendations are clearly described.

1

Reprinted in adapted format, with permission, from the AGREE Research Trust http://www.agreetrust.org. Copyright 2006 by the AGREE Research Trust.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 231
Appendix F Guideline Standards: The AGREE Instrument and COGS Checklist THE APPRAISAL OF GUIDELINES RESEARCH AND EVALUATION (AGREE) INSTRUMENT1 Scope and Purpose 1. The overall objective(s) of the guideline is (are) specifically described. 2. The clinical question(s) covered by the guideline is (are) specifically described. 3. The patients to whom the guideline is meant to apply are specifically described. Stakeholder Involvement 4. The guideline development group includes individuals from all the relevant professional groups. 5. The patients’ views and preferences have been sought. 6. The target users of the guideline are clearly defined. 7. The guideline has been piloted among target users. Rigour of Development 8. Systematic methods were used to search for evidence. 9. The criteria for selecting the evidence are clearly described. 10. The methods used for formulating the recommendations are clearly described. 1 Reprintedin adapted format, with permission, from the AGREE Research Trust http:// www.agreetrust.org. Copyright 2006 by the AGREE Research Trust. 

OCR for page 231
 KNOWING WHAT WORKS IN HEALTH CARE 11. The health benefits, side effects and risks have been considered in formulating the recommendations. 12. There is an explicit link between the recommendations and the sup- porting evidence. 13. The guideline has been externally reviewed by experts prior to its publication. 14. A procedure for updating the guideline is provided. Clarity and Presentation 15. The recommendations are specific and unambiguous. 16. The different options for management of the condition are clearly presented. 17. Key recommendations are easily identifiable. 18. The guideline is supported with tools for application. Applicability 19. The potential organisational barriers in applying the recommenda- tions have been discussed. 20. The potential cost implications of applying the recommendations have been considered. 21. The guideline presents key review criteria for monitoring and/or audit purposes. Editorial Independence 22. The guideline is editorially independent from the funding body. 23. Conflicts of interest of guideline development members have been recorded.

OCR for page 231
 APPENDIX F CONFERENCE ON GUIDELINES STANDARDIZATION (COGS) CHECKLIST FOR REPORTING CLINICAL PRACTICE GUIDELINES2 Topic Description 1. Overview material Provide a structured abstract that includes the guideline’s release date, status (original, revised, updated), and print and electronic sources. 2. Focus Describe the primary disease/condition and intervention/service/technology that the guideline addresses. Indicate any alternative preventive, diagnostic or therapeutic interventions that were considered during development. 3. Goal Describe the goal that following the guideline is expected to achieve, including the rationale for development of a guideline on this topic. 4. Users/setting Describe the intended users of the guideline (e.g., provider types, patients) and the settings in which the guideline is intended to be used. 5. Target population Describe the patient population eligible for guideline recommendations and list any exclusion criteria. 6. Developer Identify the organization(s) responsible for guideline development and the names/ credentials/potential conflicts of interest of individuals involved in the guideline’s development. 7. Funding Identify the funding source/sponsor and source/sponsor describe its role in developing and/or reporting the guideline. Disclose potential conflict of interest. 8. Evidence Describe the methods used to search the Collection scientific literature, including the range of dates and databases searched, and criteria applied to filter the retrieved evidence. 2 Reprinted,with permission, from Annals of Internal Medicine 2003. Copyright 2007 by the American College of Physicians.

OCR for page 231
 KNOWING WHAT WORKS IN HEALTH CARE Topic Description 9. Recommendation Describe the criteria used to rate the quality of grading criteria evidence that supports the recommendations and the system for describing the strength of the recommendations. Recommendation strength communicates the importance of adherence to a recommendation and is based on both the quality of the evidence and the magnitude of anticipated benefits or harms. 10. Method for Describe how evidence was used to create synthesizing recommendations, e.g., evidence tables, meta- evidence analysis, decision analysis. 11. Prerelease review Describe how the guideline developer reviewed and/or tested the guidelines prior to release. 12. Update plan State whether or not there is a plan to update the guideline and, if applicable, an expiration date for this version of the guideline. 13. Definitions Define unfamiliar terms and those critical to correct application of the guideline that might be subject to misinterpretation. 14. Recommendations State the recommended action precisely and and rationale the specific circumstances under which to perform it. Justify each recommendation by describing the linkage between the recommendation and its supporting evidence. Indicate the quality of evidence and the recommendation strength, based on the criteria described in 9. 15. Potential benefits Describe anticipated benefits and potential and harms risks associated with implementation of guideline recommendations. 16. Patient Describe the role of patient preferences when a preferences recommendation involves a substantial element of personal choice or values. 17. Algorithm Provide (when appropriate) a graphical description of the stages and decisions in clinical care described by the guideline.

OCR for page 231
 APPENDIX F Topic Description 18. Implementation Describe anticipated barriers to application of considerations the recommendations. Provide reference to any auxiliary documents for providers or patients that are intended to facilitate. REFERENCES The AGREE Collaboration. 2001. The Appraisal of Guidelines for Research and Ealuation (AGREE) Instrument. London, UK: The AGREE Research Trust http://www.agreetrust. org/docs/AGREE_Instrument_English.pdf (accessed September 2007). Shiffman, R. N., P. Shekelle, M. Overhage, J. Slutsky, J. Grimshaw, and A. M. Deshpande. 2003. Standardized reporting of clinical practice guidelines: A proposal from the Confer- ence on Guideline Standardization. Annals of Internal Medicine 139(6):493-500.

OCR for page 231